| pubmed-article:17505821 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17505821 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:17505821 | lifeskim:mentions | umls-concept:C0022209 | lld:lifeskim |
| pubmed-article:17505821 | lifeskim:mentions | umls-concept:C0017431 | lld:lifeskim |
| pubmed-article:17505821 | lifeskim:mentions | umls-concept:C0031437 | lld:lifeskim |
| pubmed-article:17505821 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:17505821 | lifeskim:mentions | umls-concept:C0851347 | lld:lifeskim |
| pubmed-article:17505821 | lifeskim:mentions | umls-concept:C0796518 | lld:lifeskim |
| pubmed-article:17505821 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:17505821 | pubmed:dateCreated | 2007-6-12 | lld:pubmed |
| pubmed-article:17505821 | pubmed:abstractText | This study evaluated the pharmacokinetics of isoniazid (INH) associated with optimal early bactericidal activity (EBA), defined as 90% of the maximum EBA (EBA(90)) and the influence of N-acetyltransferase-2 (NAT2) subtype on the ability of pulmonary tuberculosis (PTB) patients to reach the identified pharmacokinetic values after INH doses ranging from 0.2 to 10-12 mg/kg body weight. | lld:pubmed |
| pubmed-article:17505821 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17505821 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17505821 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17505821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17505821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17505821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17505821 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17505821 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17505821 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:17505821 | pubmed:issn | 0031-6970 | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:DonaldP RPR | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:SirgelF AFA | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:van HeldenP... | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:SeifartH IHI | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:ParkinD PDP | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:SchaafH SHS | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:VenterAA | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:MaritzJ SJS | lld:pubmed |
| pubmed-article:17505821 | pubmed:author | pubmed-author:WerelyC JCJ | lld:pubmed |
| pubmed-article:17505821 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17505821 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:17505821 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17505821 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17505821 | pubmed:pagination | 633-9 | lld:pubmed |
| pubmed-article:17505821 | pubmed:dateRevised | 2010-9-8 | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:meshHeading | pubmed-meshheading:17505821... | lld:pubmed |
| pubmed-article:17505821 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17505821 | pubmed:articleTitle | The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. | lld:pubmed |
| pubmed-article:17505821 | pubmed:affiliation | Paediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University, PO Box 19063, Tygerberg 7505, South Africa. prd@sun.ac.z | lld:pubmed |
| pubmed-article:17505821 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17505821 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17505821 | lld:pubmed |
